Moderate-To-Severe Atopic Dermatitis

The FDA approved an expanded indication for tralokinumab-ldrm to include children aged 12 to 17 years with moderate to severe atopic dermatitis not adequately controlled with topical therapies, according to a press release from Leo Pharma.

Amy S. Paller, MD, of Northwestern University Feinberg School of Medicine, discussed how to approach treatment of mild-to-moderate vs. moderate-to-severe atopic dermatitis.